Slide 1: 9M 2020 order intake
9M 2020 order intake Greg Poux-Guillaume, CEO | Jill Lee, CFO | October 29, 2020
Slide 2: The safe harbor statement under the US private securities litigation reform act 1995
The safe harbor statement under the US private securities litigation reform act 1995 This presentation may contain forward-looking statements, including but not limited to, projections of financial developments, market activities or future performance of products and solutions, containing risks and
Slide 3: 9M order intake
9M order intake 9M 2020 order intake
Slide 4: 9M 2020 highlights
9M 2020 highlights • YTD orders 2’614m, –2.0% FX adjusted, –3.6% organic • Q3 orders 774m, –9.9% FX adjusted and organic • PE and RES bottomed out in July/Aug. on project shifts and site access restrictions, rebound in Sept. to continue in Q4 • CT flat YoY in Q3 despite low July/Aug., rebound in Sep
Slide 5: Pumps Equipment
Pumps Equipment Water and Industry performing well, Energy ramped down as anticipated Order intake (in CHF millions) Highlights 9M 20 9M 19 YOY adj.1 org.2 • Q3 orders: 275m; –18.7% adj.; –17.8% org. 1’019 1’119 –8.9% –2.1% –0.9% • Energy lower on global slowdown in O&G + price discipline given good
Slide 6: Rotating Equipment Services
Rotating Equipment Services Strong September after summer impacted by site access restrictions Order intake (in CHF millions) Highlights 9M 20 9M 19 YOY adj.1 org.2 • Q3 orders: 264m; –7.1% adj. and org. 881 910 –3.2% 4.3% 1.7% • Significant FX impact 22m in Q3 and 68m YTD • Soft July and August due
Slide 7: Chemtech
Chemtech Q3 orders holding up on China growth Order intake (in CHF millions) Highlights 9M 20 9M 19 YOY adj.1 org.2 • Q3 orders: 140m; +1.2% adj.; –0.9% org. 459 500 –8.2% –1.9% –8.7% • Clear pick up of commercial projects in our Bio-Based and Renewable technologies group • Tower Field Services lowe
Slide 8: Applicator Systems
Applicator Systems Last two months above 2019 levels Order intake (in CHF millions) Highlights 9M 20 9M 19 YOY adj.1 org.2 • Q3 orders at 95m (> 2x Q2); –2.9% adj. and org. 255 329 –22.6% –19.8% –19.8% • Beauty and Adhesives at Q3 2019 level • Dental at 90% of Q3 2019 • Aug. and Sept. above 2019 on
Slide 9: Haselmeier acquisition
Haselmeier acquisition 9M 2020 order intake
Slide 10: Delivering on our 2016 strategic vision
Delivering on our 2016 strategic vision Building the medical segment of Applicator Systems • On July 4 2016, we announced Excerpt from presentation published on July 4, 2016* • the creation of our Beauty (micro-brush applicator) * Terminology adjusted segment through the acquisition of Geka • the am
Slide 11: Haselmeier in sweet-spot for growth
Haselmeier in sweet-spot for growth Underlying markets with long-term growth trends • More drugs such as biologics and biosimilars with complex Attractive and versatile product portfolio (own IP) active substances need to be injected • Injecting at home, i.e. self medication, is driving pen and auto
Slide 12: Future-proof new flagship platform
Future-proof new flagship platform D-Flex: Disposable pen platform for fixed or variable doses High quality pharma Digital ready: Connected Cap customers require: ✓ Flexible ▪ High flexibility for smaller and midsize volumes ✓ Fast track ▪ Short time to market ▪ Smart data ✓ Own-IP: management for ▪
Slide 13: Ambition for Haselmeier
Ambition for Haselmeier Remove self-induced restrictions to capitalize on product innovation engine Targeted development of sales and EBITDA margin in EUR millions; FY-end Sep 2019 EBITDA margin • Own-IP pen drug delivery systems 90 • Clean room manufacturing capabilities • Growing number of pharma
Slide 14: Summary & Outlook
Summary & Outlook 9M 2020 order intake
Slide 15: Summary and Outlook
Summary • Orders bottomed over summer, Q3 10% below high Q3 ‘19 baseline on project shifts and site access restrictions • Recovery in September carrying into Q4 • APS rebound confirmed, orders last 2 months > 2019 • Acquisition of Haselmeier closed October 1 Outlook • FY20 orders –3% to –4% org. on
Slide 16: Your Investor Relations contact
Your Investor Relations contact Christoph Ladner Head of Investor Relations Sulzer Management Ltd Phone: +41 52 262 30 22 Neuwiesenstrasse 15 Mobile: +41 79 326 69 70 8401 Winterthur E-mail: christoph.ladner@sulzer.com Switzerland www.sulzer.com